LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, a clinical-stage immuno-oncology company developing an immune-activating antibody therapeutic designed by leveraging an AI platform, today announced positive Phase 2 data from its ongoing Phase 1/2 study of imneskibart in patients with doublet checkpoint inhibitor (CPI)-refractory metastatic melanoma. The data will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting in Chicago, Illinois. Th